Showing 1 - 10 results of 10 for search 'Matthew G. Krebs', query time: 0.04s
Refine Results
-
1
Circulating tumour cells: their utility in cancer management and predicting outcomes by Matthew G. Krebs, Jian-Mei Hou, Tim H. Ward, Fiona H. Blackhall, Caroline Dive
Published 2010-11-01
Article -
2
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition by Athanasios R Paliouras, Marta Buzzetti, Lei Shi, Ian J Donaldson, Peter Magee, Sudhakar Sahoo, Hui‐Sun Leong, Matteo Fassan, Matthew Carter, Gianpiero Di Leva, Matthew G Krebs, Fiona Blackhall, Christine M Lovly, Michela Garofalo
Published 2020-06-01
Article -
3
Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastas... by Qing Zhang, PhD, Jessica J. Lin, MD, Navdeep Pal, M.B.B.S., MPH, Letizia Polito, PhD, Huong Trinh, MD, Magalie Hilton, MSc, Vlatka Smoljanović, MD, Nino Kurtsikidze, MD, Venice Archer, MD, Matthew G. Krebs, MD, PhD
Published 2023-04-01
Article -
4
A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary by Alicia-Marie Conway, Simon P. Pearce, Alexandra Clipson, Steven M. Hill, Francesca Chemi, Dan Slane-Tan, Saba Ferdous, A. S. Md Mukarram Hossain, Katarzyna Kamieniecka, Daniel J. White, Claire Mitchell, Alastair Kerr, Matthew G. Krebs, Gerard Brady, Caroline Dive, Natalie Cook, Dominic G. Rothwell
Published 2024-04-01
Article -
5
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1... by Matthew G. Krebs, MD, Martin Forster, MD, PhD, Margarita Majem, MD, PhD, Julio Peguero, MD, Wade Iams, MD, Tim Clay, MD, Patricia Roxburgh, MD, PhD, Bernard Doger, MD, PhD, Pawan Bajaj, MD, Andres Barba, MD, Suvini Perera, MS, Christian Mueller, MS, Frédéric Triebel, MD, PhD
Published 2024-11-01
Article -
6
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib by R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Published 2023-08-01
Article -
7
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib by R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Published 2025-03-01
Article -
8
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib by R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Published 2023-07-01
Article -
9
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe by Kjetil Taskén, Soemeya F. Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G. Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A. Lowery, Matthew G. Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Published 2024-05-01
Article -
10
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC by Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD
Published 2022-06-01
Article